Valneva gains after new Phase 3 data for chikungunya vaccine in adolescents

Medical form with diagnosis Chikungunya in a hospital.

designer491/iStock via Getty Images

Valneva (NASDAQ:VALN) ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved chikungunya vaccine, Ixchiq, from a Phase 3 trial for people aged 12–17 years old in Brazil.

According to the company, new

Leave a Reply

Your email address will not be published. Required fields are marked *